Responsibility in Drug Advertising Act of 2025
Summary
What This Bill Does
The Responsibility in Drug Advertising Act amends the Food, Drug, and Cosmetic Act to make direct-to-consumer advertising of a newly approved drug unlawful for the first three years after approval. The restriction covers social media. A sponsor can apply for a waiver during the third year, and FDA may grant it only if direct-to-consumer advertising would have affirmative value to public health. After the three-year period, FDA may still prohibit direct-to-consumer advertising if the drug has significant adverse health effects based on post-approval data. The bill shifts early post-approval marketing from consumer demand generation toward safety monitoring and physician-mediated prescribing.
Who Benefits and How
Patients benefit because newly approved drugs would not be mass-marketed directly to consumers before three years of post-approval experience. Physicians benefit from less patient pressure generated by early consumer advertising for new prescription drugs. FDA safety reviewers benefit from authority to keep consumer advertising off the market when post-approval data show significant adverse effects. Public health advocates benefit from a waiver standard tied to affirmative public-health value rather than sponsor marketing interest.
Who Bears the Burden and How
Drug manufacturers must delay consumer advertising for newly approved drugs and seek waivers only under FDA procedures. Pharmaceutical marketing departments lose early social-media and direct-to-consumer advertising channels. FDA must review waiver applications and determine whether advertising has affirmative public-health value. Advertising platforms lose potential revenue from new-drug consumer campaigns during the restricted period.
Key Provisions
- Prohibits direct-to-consumer advertising for newly approved drugs during the first three years after approval.
- Includes social media platforms in the advertising restriction.
- Authorizes a third-year waiver only when FDA finds affirmative public-health value.
- Allows FDA to prohibit later direct-to-consumer advertising for drugs with significant adverse health effects.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Bars direct-to-consumer advertising, including social-media advertising, for newly approved drugs for three years, with a possible third-year public-health waiver and authority to prohibit later ads for drugs with significant adverse health effects.
Key Policy Areas
Pharmaceuticals, Advertising, Public Health
Primary Purpose
Bars direct-to-consumer advertising, including social-media advertising, for newly approved drugs for three years, with a possible third-year public-health waiver and authority to prohibit later ads for drugs with significant adverse health effects.
Policy Domains
Resolution provisions
Identified Gains
- Patients
- Physicians
- FDA safety reviewers
- Public health advocates
Identified Costs
- Drug manufacturers
- Pharmaceutical marketing departments
- FDA
- Advertising platforms
Legislative Progress
In CommitteeMs. DeLauro introduced the following bill; which was referred to …
Referred to the House Committee on Energy and Commerce.
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Drug manufacturers, Pharmaceutical marketing departments
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology